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Both human and murine cytomegaloviruses (HCMV and MCMV) down-regulate expression of conventional
class I major histocompatibility complex (MHC) molecules at the surfaces of infected cells. This allows the
infected cells to evade recognition by cytotoxic T cells but leaves them susceptible to natural killer cells, which
lyse cells that lack class I molecules. Both HCMV and MCMV encode class I MHC heavy-chain homologs that
may function in immune response evasion. We previously showed that a soluble form of the HCMV class I
homolog (UL18) expressed in Chinese hamster ovary cells binds the class I MHC light-chain b2-microglobulin
and a mixture of endogenous peptides (M. L. Fahnestock, J. L. Johnson, R. M. R. Feldman, J. M. Neveu, W. S.
Lane, and P. J. Bjorkman, Immunity 3:583–590, 1995). Consistent with this observation, sequence comparisons
suggest that UL18 contains the well-characterized groove that serves as the binding site in MHC molecules for
peptides derived from endogenous and foreign proteins. By contrast, the MCMV homolog (m144) contains a
substantial deletion within the counterpart of its a2 domain and might not be expected to contain a groove
capable of binding peptides. We have now expressed a soluble version of m144 and verified that it forms a heavy
chain–b2-microglobulin complex. By contrast to UL18 and classical class I MHC molecules, m144 does not
associate with endogenous peptides yet is thermally stable. These results suggest that UL18 and m144 differ
structurally and might therefore serve different functions for their respective viruses.
Cytomegaloviruses (CMVs) are ubiquitous, host-specific
pathogens that are capable of establishing lifelong infections in
immunocompetent hosts. Although acute infection will elicit
an immune response, this response usually fails to completely
resolve the infection. Instead, the virus persists in the host,
often in a state of latency, and recurrent infections may be
observed if the animal becomes immunocompromised (5). In
order to maintain this degree of persistence, especially in the
face of a fully primed immune system, CMVs have developed
various means of modulating the host immune system. One
strategy used by both human and murine CMVs (HCMV and
MCMV) is the down-regulation of host class I major histocom-
patibility complex (MHC) molecules (6). Class I MHC mole-
cules are polymorphic glycoproteins composed of a mem-
brane-bound heavy chain associated with a nonpolymorphic
light chain, b2-microglobulin (b2m). Class I molecules present
peptides derived from the degradation of cytoplasmic proteins
to cytotoxic T cells, thus enabling them to survey the status of
the interior of the cell (49). In an uninfected cell, MHC mol-
ecules bind peptides derived from self proteins to which T cells
are tolerant. However, in an infected cell, some MHC mole-
cules are occupied by peptides derived from viral proteins, to
which T cells react by killing the cell. By down-regulating MHC
class I molecules, viruses are able to elude viral-antigen-spe-
cific cytotoxic T cells.
Although interference with class I-mediated antigen presen-
tation or class I expression may enable infected cells to evade
virus-specific T cells, it may also render these cells susceptible
to detection and lysis by NK cells. NK cells express both acti-
vating and inhibitory surface receptors (31). The activating
receptors are predominantly triggered by non-MHC mole-
cules, while the inhibitory receptors recognize class I MHC
molecules (31). Stimulation of activating receptors leads to
target cell lysis unless the NK cell inhibitory receptors are able
to engage an adequate level of self class I molecules on the
target cell (27). Therefore, those cells that have down-regu-
lated their class I molecules to a level sufficient to avoid T cells
can be recognized and eliminated by NK cells.
As a possible means of undermining the host NK cell re-
sponse, both HCMV and MCMV encode MHC class I ho-
mologs (2, 14, 39). It has been hypothesized that the role of
these homologs in a virus-infected cell is to engage NK cell
inhibitory receptors, thereby preventing the lysis that would
normally occur due to down-regulation of class I molecules
(11, 14, 40). In this way virus-infected cells are less susceptible
to lysis by both cytotoxic T lymphocytes and NK cells. The
HCMV-encoded homolog, UL18, is a 348-residue type I trans-
membrane glycoprotein whose extracellular region shares
;25% amino acid sequence identity with the extracellular re-
gions of human class I molecules (2) (Fig. 1A). Like class I
MHC molecules, UL18 associates with b2m (6). We previously
showed that a soluble form of UL18 expressed in Chinese
hamster ovary (CHO) cells binds a mixture of endogenous
peptides with characteristics similar to those of peptides eluted
from class I molecules, that is, “anchor” residues, and a pre-
dominance of short peptides derived from cytoplasmic proteins
(11). The MCMV-encoded MHC homolog, m144, is a 383-
residue type I transmembrane glycoprotein whose extracellular
region shares ;25% amino acid sequence identity with the
corresponding part of murine class I MHC extracellular re-
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gions (14, 39) (Fig. 1A). The two viral homologs are not closely
related to each other, sharing only 18% sequence identity, thus
requiring that m144 be separately characterized.
In this paper we describe the expression and biochemical
characterization of a soluble version of m144. We find that, like
UL18 and class I MHC molecules, m144 binds b2m, but unlike
these other proteins, it does not associate with endogenous
peptides. We further demonstrate that m144 is thermally sta-
ble in the absence of bound peptide, unlike both class I MHC
molecules (13, 33, 46, 50) and UL18. Taken together with a
sequence comparison of m144 with class I MHC molecules,
these results suggest that the m144 counterpart of the MHC
peptide-binding site differs from those of both class I mole-
cules and UL18 (Fig. 1B).
MATERIALS AND METHODS
Construction of the m144 expression plasmid. Molecular cloning manipula-
tions were performed by standard protocols (43). PCR was used to insert a 59
XhoI site, a 39 NotI site, and a stop codon after the codon corresponding to
amino acid 241 of the m144 gene (the HindIII fragment I of MCMV strain K181
was kindly provided by Helen Farrell, University of Western Australia, Ned-
lands). Our numbering scheme starts with the first residue of the mature protein,
which is designated residue 1, and all other residues are numbered sequentially
(see “N-terminal sequencing of purified m144” below). The PCR product was
cloned into pBSIISK1 (Stratagene), and the sequence was verified. The modified
m144 gene was then removed from pBSIISK1 by using XhoI and NotI and was
subcloned into the unique XhoI and NotI sites of the expression vector PBJ5-GS
(16). PBJ5-GS carries the glutamine synthetase gene as a selectable marker and
as a means of gene amplification in the presence of the drug methionine sul-
foximine, a system developed by Celltech (1).
Construction of the murine b2m (b allele) expression plasmid. An expression
plasmid containing the a allele of murine b2m (mb2ma) was previously con-
structed in our laboratory (12). This allele of b2m, however, is not recognized by
the anti-mb2m monoclonal antibody (MAb) S19.8 (48). Originally anticipating
that m144-mb2m heterodimers could be purified by S19.8 immunoaffinity chro-
matography, we used site-directed mutagenesis to change mb2ma to mb2mb.
This mb2ma gene was excised by using XbaI and XhoI and was subcloned into the
same sites in pBSKS1 (Stratagene). The a and b alleles of mb2m differ by only
1 nucleotide, which changes residue 85 from Asp to Ala (15). The single nucle-
otide was altered by oligonucleotide-directed in vitro mutagenesis (29), and the
sequence was verified. The modified mb2m gene was then removed from pB-
SKS1 by using XbaI and XhoI and was subcloned into the unique XbaI and XhoI
sites of the expression vector PBJ1 (32). Unfortunately, the mb2mb epitope
recognized by the antibody S19.8 is inaccessible when the protein is complexed
to the m144 heavy chain, as verified in immunoprecipitation experiments (data
not shown).
Cell culture and transfection. The m144 expression plasmid was cotransfected
with either a human b2m (hb2m) (13) expression vector or the previously
described mb2m expression vector into CHO cells by a Lipofectin procedure
(GIBCO BRL). Cells resistant to 100 mM methionine sulfoximine were selected
according to the protocol established by Celltech, modification of which has been
previously described (16). Transfected CHO cells were maintained in glutamine-
free a minimal essential medium (Irvine Scientific) supplemented with 5% dia-
lyzed fetal bovine serum (GIBCO BRL), 100 mM methionine sulfoximine (Sig-
ma), penicillin (100 U/ml), and streptomycin (100 mg/ml). Cells secreting m144-
b2m heterodimers were identified by immunoprecipitation of supernatants of
cells metabolically labeled with [35S]methionine and [35S]cysteine (see below) by
using either an antibody against hb2m (BBM.1) (36) or anti-m144 antiserum.
Clones were considered positive if immunoprecipitation yielded a heavy chain of
44 kDa and a light chain of 12 kDa. The heavy chain was verified to be m144 by
N-terminal sequencing (see below).
35S metabolic labeling. m144-transfected CHO cell lines derived from colonies
were expanded into 12-well trays, grown to confluence, and incubated for 5 h in
1.0 ml of methionine- and cysteine-free medium (GIBCO BRL) plus 1% dia-
lyzed fetal bovine serum including 5 mCi of a [35S]methionine and [35S]cysteine
(ICN) mixture. Supernatants were clarified by a 5-min spin in a microcentrifuge,
and either BBM.1 or anti-m144 antiserum (see below) was added. Immunopre-
cipitations were carried out by standard methods (21) with protein G-bearing
Sepharose beads (Pharmacia). Samples were boiled in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) running buffer and loaded onto
15% polyacrylamide gels, which were fixed, dried, and exposed to a Phosphor-
FIG. 1. Comparison of MCMV and HCMV class I homologs with class I
MHC molecules. (A) Sequence alignment of the mature extracellular regions of
m144 with a murine class I molecule (muMHC) and of UL18 with a human class
I MHC molecule (huMHC) (based on data from Fig. 1 in reference 14). Num-
bering is with reference to class I MHC molecules. Crystallographically deter-
mined secondary-structural elements in class I MHC molecules (3) are shown
above the sequences as arrows for b strands (strands 1 through 8 within the a1
and a2 domains are labeled b1 to b8, and strands 1 through 7 within the a3 domain
are labeled A to G) and spirals for a-helical regions. Positions of conserved ty-
rosines in the pocket that accommodates peptide N termini (pocket A in class I
MHC molecules [45, 47]) are marked with an asterisk, and potential N-linked
glycosylation sites are underlined. (B) Locations of UL18 and m144 sequence
insertions and deletions on the class I MHC structure. Ribbon diagrams of the
carbon-a backbone of the a1 and a2 domains of HLA-A2 (4, 45) are shown with
the locations of UL18 or m144 insertions indicated by asterisks; class I regions
that are deleted in UL18 or m144 are indicated by dashed lines. Conserved
tyrosines shared between UL18 and class I molecules are highlighted in the left
panel. This figure was generated by using Molscript (28) and Raster-3D (34).
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Imager screen (Molecular Dynamics). The image was then developed with a
Molecular Dynamics 425E phosphorimage scanner.
Protein purification. m144-hb2m- and m144-mb2m-secreting CHO cell lines
were grown to confluence in 50 10-cm plates. Supernatants were collected every
3 days for 1 month. Soluble m144-hb2m heterodimers were purified from the
supernatants on a BBM.1 immunoaffinity column. This affinity column was pre-
pared by coupling 70 mg of the BBM.1 MAb to cyanogen bromide-treated
Sepharose 4B (Pharmacia) at approximately 10 mg of antibody/ml of resin
according to the protocol of the manufacturer. Supernatants were passed over
the affinity column, which was then washed with 50 column volumes of a solution
consisting of 50 mM Tris (pH 7.4), 0.1% NaN3, and 1 mM EDTA. Free b2m and
m144-hb2m heterodimers were eluted from the BBM.1 column with 50 mM
diethylamine (pH 11.5) into tubes containing 1.0 M Tris (pH 7.4). Free hb2m was
separated from m144-hb2m heterodimers by using a Superdex 200 HR 10/30 fast
protein liquid chromatography (FPLC) filtration column. Approximately 3 mg of
m144-hb2m heterodimers was recovered per liter of transfected cell superna-
tants. Soluble m144-mb2m heterodimers were purified from the supernatants on
a 15C6 immunoaffinity column made by coupling an anti-m144 MAb (see below)
to Sepharose beads as described above. Supernatants from m144-mb2m-secret-
ing CHO cell lines were passed over the column, the column was washed, and the
protein was eluted as described above. A second protein migrating with an
apparent molecular mass of 93 kDa coeluted with the m144-mb2m heterodimer
and was separated by using a Superdex 200 HR 10/30 FPLC filtration column.
Approximately 1 mg of m144-mb2m heterodimer was recovered per liter of
transfected cell supernatants.
N-terminal sequencing of purified m144. N-terminal sequencing was per-
formed on 2.3 mg of purified soluble m144-hb2m or m144-mb2m in a phosphate
buffer dried onto a poly(vinylidene difluoride) membrane and inserted into an
Applied Biosystems model 476A sequencer reaction cartridge. Two sequences
were isolated from the m144-hb2m sample: the sequence IQRTPKIQVYSRH
PAEN, corresponding to the first 17 residues of mature hb2m (26), and the
sequence HGTEDSSESGLRYAYT, corresponding to the first 17 residues of the
mature m144 heavy chain (reference 14 and data not shown). Two sequences
were also isolated from the m144-mb2m sample: the sequence IQKTPQIQVYS
RHPPEN, corresponding to the first 17 residues of mature mb2m (17), and the
residues given above for the m144 heavy chain.
Acid elution and characterization of peptides. Purified secreted UL18, m144-
hb2m, m144-mb2m, FcRn (a class I MHC homolog that functions as a receptor
for the Fc portions of immunoglobulin G [16]), and H2-Kd-hb2m (a murine class
I MHC heavy chain complexed with hb2m [13]) proteins were analyzed for the
presence of bound peptides. All these proteins were produced in CHO cells as
described above for m144. In these experiments, FcRn served as the negative
control, since it had previously been established by biochemical and crystallo-
graphic methods that it does not associate with endogenous peptides (7, 37),
while UL18 and Kd served as positive controls, since endogenous peptides had
previously been characterized from samples of these proteins (11, 37). Acid
elutions and sequencing were performed by established methods (24, 42, 51).
Briefly, 0.25 mg of protein was concentrated to 100 ml in a Centricon 3 (molec-
ular weight cutoff, 3,000) ultrafiltration device (Amicon; Beverly, Mass.). After
dilution with 1.0 ml of 50 mM ammonium acetate (pH 7.5), the proteins were
again concentrated to 100 ml, and this procedure was repeated. The washed
protein was then treated with 1.0 ml of 12% acetic acid, heated to 70°C for 5 min,
and subsequently concentrated again to 100 ml in the ultrafiltration unit, with the
filtrate containing any eluted material. This elution step was then repeated. The
acid eluates were lyophilized and analyzed by automated Edman degradation
with an Applied Biosystems model 476A protein sequencer (see Table 1). Elu-
ates were also analyzed with a Perkin-Elmer/Applied Biosystems Inc. model 172A
microbore high-pressure liquid chromatograph (HPLC) and a Reliasil C18 (Reliasil
Column Engineering) column. Material was eluted by using a 3-ml gradient from
0.05% trifluoroacetic acid in water to 0.05% trifluoroacetic acid in 40% acetoni-
trile. Absorbance was monitored at 200 nm. The fractions containing peaks were
analyzed by matrix-assisted, laser desorption, time-of-flight mass spectrometry
with a PerSeptive Biosystems (Farmingham, Mass.) ELITE mass spectrometer.
CD analyses. An Aviv 62A DS spectropolarimeter equipped with a thermo-
electric cell holder was used for circular dichroism (CD) measurements. Wave-
length scans and thermal denaturation curves were obtained from samples con-
taining 10 mM protein in 5 mM phosphate at pH 7 by using a 0.1-mm path length
cell for wavelength scans and a 1-mm path length cell for thermal denaturation
measurements. The heat-induced unfolding of UL18, m144-hb2m, m144-mb2m,
and H2-Kd-hb2m was monitored by recording the CD signal at 223 nm while the
sample temperature was raised from 25 to 75°C at a rate of approximately
0.7°C/min. The transition midpoint (Tm) for each curve was determined by taking
the maximum of a plot of du/dT versus T (where u is ellipticity) after averaging
the data with a moving window of 5 points.
Production of MAbs and polyclonal antiserum. Three MAbs were generated
for the studies presented here, two specific for m144-b2m and one specific for the
UL18 heavy chain. Of those that recognize m144-b2m, 15C6 was raised against
a gel slice of the m144 heavy chain and 19G4 was raised against the m144-hb2m
heterodimer. Female BALB/c mice (5 weeks old) were primed and twice boosted
at 2-week intervals by intraperitoneal injection of either a 5- by 10- by 1.5-mm
homogenized gel slice containing m144 or 100 mg of purified soluble m144-
hb2m. Serum was screened 1 week after each injection by enzyme-linked immu-
nosorbent assay (ELISA). Three days preceding the fusion, one mouse was
boosted with a gel slice or 100 mg of purified m144 in phosphate-buffered saline.
Splenocytes from the boosted mouse were fused with HL-1 murine myeloma
cells, and media from the hybridoma cultures were tested for antibodies against
the m144 heavy chain by ELISA. After subcloning of positive clones at clonal
density, ascites tumors were produced in pristane-primed BALB/c mice. In
addition, a rabbit antiserum recognizing m144 was raised against a gel slice of the
m144 heavy chain (Antibodies Incorporated, Davis, Calif.). Both MAbs and the
antiserum are effective reagents in an ELISA for detection of m144-b2m, im-
munoprecipitation of soluble m144-b2m heterodimers, and Western blotting.
The UL18-specific MAb, 10C7, was prepared similarly to m144-specific MAbs;
however, the mice used were female OLA 3 BL6 hb2m transgenic mice (a kind
gift of H. Ploegh, Massachusetts Institute of Technology) injected with enzymat-
ically deglycosylated UL18-hb2m heterodimers. Several previous attempts to
isolate an antibody against the UL18 heavy chain in nontransgenic mice failed,
presumably because UL18 is heavily glycosylated (13 potential N-linked glyco-
sylation sites [2]), so that an antibody recognizing a protein epitope within UL18
rather than b2m was difficult to isolate. Indeed, all hybridomas screened from
nontransgenic mice produced antibodies that recognized hb2m instead of the
heavy chain. By using hb2m transgenic mice, many potential MAbs against the
heavy chain were generated. A rabbit antiserum recognizing UL18 was raised
against a gel slice of the UL18 heavy chain (HRP Inc., Denver, Pa.). Both the
MAb and the antiserum are effective reagents in an ELISA for detection of
UL18-hb2m, immunoprecipitation of soluble UL18-hb2m heterodimers, and
Western blotting.
Preparation of peptide-filled UL18 and H-2K
d. UL18 was purified from the
supernatants of UL18-hb2m-secreting cells (11) grown in a hollow-fiber biore-
actor device (Cell Pharm I; Unisyn Fibertec, San Diego, Calif.). Using this
system, only 35 to 40% of the molecules appear to contain endogenous peptides,
compared to UL18 produced from transfected cells grown on plates, which
appears to be fully occupied (11). As previously described (11), we calculated the
percent of UL18 occupied with peptide by comparing the amount of peptide
material eluted from H-2Kd with the amount eluted from UL18 when the number
of picomoles of starting protein is the same. The peptide ALPHAILRL, previ-
ously identified as a major component of UL18 acid eluates (11), was synthesized
with an Applied Biosystems 433A peptide synthesizer. The peptide was incu-
bated with UL18 at a 20:1 molar ratio for 12 h at room temperature. Unbound
peptides were separated from UL18 by passing the mixture over a Superdex 200
HR 10/30 FPLC size exclusion column. H-2Kd was purified from supernatants of
Kd-hb2m-secreting cells grown on 10-cm plates. Previous characterization of
soluble Kd established that ;70% of the protein is empty and ;30% is occupied
by endogenous peptide (13). The peptide SYIPSAEKI, previously identified as a
Kd-binding peptide (12, 41), was synthesized and incubated with partially empty
Kd, and unbound peptide was separated from Kd-peptide complexes as described
above for preparation of peptide-filled UL18.
RESULTS
Soluble m144 associates with hb2m and mb2m. To investi-
gate whether m144 binds b2m and serves as a peptide receptor,
we expressed a soluble version of m144 in CHO cells together
with hb2m or mb2m. The soluble version of m144 was con-
structed by truncating the gene prior to the predicted trans-
membrane region (following residue 241 of the mature pro-
tein). Initial experiments were performed with the hb2m gene
in order to facilitate detection of the protein product with the
antibody BBM.1 (36), which binds to hb2m but not to mb2m.
Transfected cells were screened by immunoprecipitating met-
abolically labeled supernatants with BBM.1. SDS-PAGE anal-
ysis of protein from positive clones revealed two bands, one
having an apparent molecular mass of 45 kDa (consistent with
its identity as truncated m144) and the other having an appar-
ent molecular mass of 12 kDa, corresponding to b2m. The
calculated molecular mass of truncated m144 is 27 kDa, but the
protein is glycosylated (4 potential N-linked glycosylation sites
[14, 39]) and would be expected to migrate with a higher
apparent molecular mass. Supernatants from positive clones
were passed over a BBM.1 immunoaffinity column, eluted,
then passed over a size exclusion column to separate free b2m
from b2m-heavy chain heterodimers. An SDS-PAGE gel of
the resulting purified protein is shown in Fig. 2. N-terminal
sequencing of purified heterodimers confirmed the sequences
of the first 17 residues of the mature forms of hb2m (26) and
m144 (14, 39).
Soluble m144 was used to produce MAbs that could be used
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to recognize m144 when complexed with mb2m. Two antibod-
ies were produced: 15C6, which was raised against a gel slice of
the m144 heavy chain, and 19G4, which was raised against
purified m144-hb2m heterodimers. CHO cells were trans-
fected with genes encoding truncated m144 and the b allele of
mb2m. Cells expressing m144-mb2m heterodimers could be
identified by immunoprecipitation with either the anti-m144
MAbs or a polyclonal anti-b2m antiserum that recognizes
mb2m, but not by immunoprecipitation with the MAb S19.8
(48), which apparently does not react with mb2mb complexed
with m144. SDS-PAGE analysis of immunoprecipitated pro-
tein from cells expressing m144 and mb2m also reveals two
bands migrating at 45 and 12 kDa (data not shown). m144-
mb2m was purified from transfected cell supernatants on an
immunoaffinity column constructed with MAb 15C6 (Fig. 2).
N-terminal sequencing of purified protein established that the
heterodimer was composed of the mature forms of m144 and
mb2m. Sequences of hamster (16) and bovine (20) b2m were
not detected, indicating that m144 was not associating with
endogenous hamster b2m or exchanging with bovine b2m in
the medium, as can occur when mouse class I MHC proteins
are expressed with mb2m in CHO cells (13).
m144 does not bind endogenous peptides. To determine if
either m144-hb2m or m144-mb2m binds peptides, purified
proteins were treated with acetic acid to dissociate potential
peptide material (24, 42, 51). Acid eluates were characterized
by N-terminal sequencing (see Table 1), HPLC, and mass
spectrometry. Soluble versions of other proteins expressed in
CHO cells (the murine class I MHC molecule H2-Kd and two
other MHC class I homologs, UL18 from HCMV and the rat
neonatal Fc receptor, FcRn) were subjected to the same treat-
ment. Kd and UL18 had previously been shown to bind pep-
tides and were used as positive controls (10, 11, 37). FcRn does
not bind peptides (7, 37) and was used as a negative control.
The characteristics of the peptides isolated from Kd and
UL18 were similar to those previously reported (11, 37) and
consistent with the known requirement for a tyrosine anchor at
position 2 for Kd (38) and a leucine or methionine anchor at
position 2 for UL18 (11) (Table 1). An aliquot of the UL18 acid
eluate was passed over a reverse-phase HPLC column, several
peaks were collected, and a number of these were character-
ized by mass spectrometry. This procedure resulted in identi-
fication of multiple peptides in the UL18 acid eluate whose
exact molecular weights corresponded to the sequences of pep-
tides previously shown to be associated with UL18 (reference
11 and data not shown).
By contrast, the low-molecular-weight acid eluates from
m144-hb2m, m144-mb2m, and FcRn did not show the pres-
ence of peptides (Table 1). With the exception of cycle 1, which
is typically subject to high backgrounds, the total yield of the
amino acids from each cycle of pool sequencing of the acid
eluates remained nearly constant, and this yield was only
slightly above background. In addition, most of the peaks in
the HPLC profile of the m144-hb2m acid eluate were also
apparent in eluates extracted from FcRn, and all were barely
notable above the background. When the few peaks that dif-
fered between the m144-hbm and FcRn eluates were collected
and characterized by mass spectrometry, these peaks were
found to contain low-molecular-weight material that did not
show proteinaceous characteristics (data not shown).
m144, but not UL18, is thermally stable in the absence of
peptides. Class I MHC heavy chains show decreased stability in
the absence of bound peptide (13, 33, 50). To ascertain if
m144-hb2m or m144-mb2m is unstable due to the absence of
bound peptide, we monitored the heat-induced unfolding of
these proteins by recording the CD signal at 223 nm while
increasing the sample temperature from 25 to 75°C (Fig. 3A).
The results were compared with melting curves of partially
empty and peptide-filled forms of the class I MHC molecule
H-2Kd (Fig. 3B) (13). Two unfolding transitions are evident in
the curve derived from m144-hb2m. The first, with a Tm of
55°C, corresponds to the unfolding of the m144 heavy chain,
while the second, with a Tm of 64°C, corresponds to the pre-
viously observed Tm for hb2m (13) and represents the inde-
pendent unfolding of the light chain subsequent to heavy-chain
denaturation. m144-mb2m melts less cooperatively than m144-
hb2m and the derived Tm for the heavy-chain unfolding (52°C)
is slightly lower, indicating that m144 complexed with mb2m is
somewhat less stable than m144 complexed with hb2m. In
addition, the downward-sloping transition for the melting of
b2m is not apparent in the melting curve of m144-mb2m,
perhaps being obscured by the CD signal from the melted
m144 heavy chain. Similar results were obtained for the melt-
ing of Kd complexed with mb2m (12). The melting behavior of
FIG. 2. SDS-PAGE (15% polyacrylamide) analysis of UL18 and the two
forms of m144. Proteins were purified from the supernatants of transfected CHO
cells by passage over an immunoaffinity column followed by size exclusion chro-
matography. The heavy chains of both heterodimers migrate with a higher
apparent molecular mass than is suggested by the mass of their protein back-
bones due to the addition of N-linked glycosides (UL18 contains 13, and m144
contains 4, potential N-linked glycosylation sites).
TABLE 1. Amino acids recovered from acid elutionsa
Cycle
Yield (pmol) of:
UL18 H-2Kd-hb2m FcRn m144-hb2m m144-mb2mb
1 86 84.5 5.9 13.7 7.3
2 75.1c 51.1d 4.7 0 1.5
3 36.9e 33.6 0.7 0.5 0.3
4 19.8 12.3 7.6 1.2 0.3
5 11.3 18.2 0 0.7 0.2
6 4.0 30.8 0 1.0 0.1
7 3.7 1.1 0.2 1.6 0.1
8 6.5 3.1 0.6 2.0 1.6
9 4.3 12.1 9.5 0.2 0.3
10 1.3 7.5 0.3 0.1 1.2
11 0.4 10.1 0.5 0.3 0.2
12 2.5 6.7 0.8 0.1 0.5
a The total yield of amino acids from each sequencing cycle is presented for
acid eluates derived from equivalent amounts of soluble UL18, Kd-hb2m, FcRn,
m144-hb2m, and m144-mb2m heterodimers. Only those amino acid residues that
showed an increase in the absolute amount recovered compared to the previous
cycle were considered significant. Results for the FcRn, Kd, and UL18 eluates are
similar to those previously reported (11, 37) in which soluble UL18 and Kd, but
not FcRn, were shown to bind endogenous peptides.
b Acid elution contributions from Asp, Glu, and Gly were not included in the
m144-mb2m tabulation because the first four cycles showed unusually high yields
that were also present in the negative control.
c Leu, Met 5 71.
d Tyr 5 25.
e Pro 5 19.
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both forms of m144 is more similar to that of peptide-filled Kd
(Tm 5 56°C for K
d-mb2m; Tm 5 57°C for K
d-hb2m) than to
that of empty Kd (Tm 5 42°C for K
d-mb2m; Tm 5 45°C for
Kd-hb2m) (12, 13) (compare Fig. 3A and B), suggesting that
m144 is thermally stable in the absence of peptide.
By contrast, thermal-stability profiles of UL18 indicate that
UL18 is only marginally stable in the absence of added peptide
(Fig. 3C). The UL18 protein produced from transfected CHO
cells grown in a hollow-fiber bioreactor is estimated to be only
40% occupied with endogenous peptide (see Materials and
Methods). This form of UL18 melts with a Tm of 41°C. Upon
addition of a known UL18-binding peptide (11), the Tm in-
creases to 66°C (Fig. 3C).
CD spectral comparison of m144, UL18, FcRn, and class I
MHC. The far-UV CD spectrum of m144 was compared with
spectra of other MHC homologs and a classical class I mole-
cule (Fig. 4). Far-UV CD spectra were previously used to
characterize the secondary structures of class I MHC mole-
cules and FcRn (16, 18, 30). The available crystal structures of
FcRn and class I molecules (7, 47) can be used to verify the
conclusion derived from the CD spectra that the secondary-
structure arrangement of FcRn resembles, but is not identical
to, class I MHC structures. The spectra of all four molecules
(m144-hb2m, UL18, FcRn, and H-2K
d) show characteristics of
proteins that are composed primarily of b-structure with a
minor a-helical conformation (25). However, the short-wave-
length portion of the m144 spectrum is red-shifted compared
with the H-2Kd and UL18 spectra and with part of the FcRn
spectrum. These results suggest that m144 has structural fea-
tures that distinguish it from UL18 and classical class I mole-
cules. Since all three types of proteins share the common
feature of b2m binding, it is likely that structural differences
are localized to regions distal from b2m, such as the top sur-
face of the a1a2 platform (Fig. 1).
DISCUSSION
HCMV and MCMV both encode class I MHC homologs.
Previous studies indicated that UL18, the HCMV class I ho-
molog, binds the class I light chain b2m (6) and associates with
endogenous peptides (11). In this study, we expressed a soluble
version of the MCMV class I homolog m144 and compared its
biochemical characteristics to those of class I molecules and
UL18. We found that m144 expressed in CHO cells associates
with both hb2m and mb2m, implying that m144 heterodimer-
izes with host-derived b2m in virus-infected cells. However,
unlike UL18 and class I molecules, m144 does not bind endog-
enous peptides, since we do not detect peptide material asso-
ciated with either form of m144-b2m. Other class I MHC
homologs for which biochemical or structural studies do not
reveal the presence of endogenous peptides include FcRn (7,
37), human Zn-a2-glycoprotein (44), and the hemochromato-
sis gene product HFE (31a). In addition, human MICA and
mouse H-2T region-encoded molecules are stably expressed in
cells that lack a functional peptide transporter, suggesting that
they too do not bind conventional class I peptide ligands (9, 19,
23, 52).
A comparison of alignments of the m144 and UL18 se-
quences with class I MHC sequences reveals that UL18 is more
likely than m144 to adopt a fold that includes an MHC-like
peptide-binding groove (Fig. 1B). Peptides bind to class I
MHC molecules in a groove located between two a-helices
that span an 8-stranded b-pleated sheet. Peptide termini are
FIG. 3. Thermal denaturation profiles. The CD signal at 223 nm is plotted as
molar ellipticity per mean residue after smoothing as a function of increasing
temperature. Tms (indicated by arrows) were determined by taking the maximum
of a plot of du/dT versus T (where u is ellipticity) after averaging the data with a
moving window of 5 points. (A) m144-hb2m and m144-mb2m melting curves. (B)
Kd-hb2m melting curves in the presence and absence of added peptide (see also
references 12 and 13). (C) UL18 melting curves in the presence and absence of
added peptide.
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accommodated in pockets at each end of the groove that are
lined with conserved residues (reviewed in reference 47). The
peptide N terminus binds in pocket A on the left side of the
groove (as depicted in Fig. 1B), in which four conserved ty-
rosines make critical hydrogen bonds to main-chain atoms of
the peptide (residues 7, 59, 159, and 171; class I numbering)
(Fig. 1A). These tyrosines are also found in the UL18 se-
quence, suggesting a similar mechanism for interaction with
peptide N termini (11). While the UL18 sequence shows some
gaps and insertions compared to class I sequences, these are
primarily confined to regions corresponding to the right side of
the groove and suggest that the UL18 structure may differ from
MHC structures in the region of the groove that interacts with
peptide C termini. Indeed, analysis of endogenous peptides
associated with UL18 revealed variability in the length of
bound peptides (11), whereas classical class I molecules show
a strong preference for binding octamer and nonamer peptides
(reviewed in reference 47). By contrast, only two of the four
pocket A tyrosines are conserved in the m144 sequence (Fig.
1A). Furthermore, the a2 domain of m144 is significantly trun-
cated compared to those of class I and UL18 molecules, such
that b strands 6 and 8 are much shorter, there is no predicted
seventh strand, and there is a large deletion within the pre-
dicted a2 domain helix. These characteristics do not seem
compatible with formation of a functional peptide-binding
groove, and they imply that this region of m144 is structurally
distinct from class I molecules and UL18. Far-UV CD spectral
differences support this prediction (Fig. 4).
Our finding that m144, unlike class I MHC molecules and
UL18, is thermally stable in the absence of bound peptide is
also consistent with a structural rearrangement in the counter-
part of its peptide-binding region. CD melting curves of m144
complexed with either hb2m or mb2m show that it is more
stable than either an empty class I molecule or partially empty
UL18 (Fig. 3). The melting curves of the empty forms of class
I and UL18 were characterized by Tms between 42 and 45°C,
while the Tm of the m144-hb2m curve was 55°C, closer to the
Tm for peptide-filled K
d (56 to 57°C) (12, 13). m144 is slightly
less stable when complexed with mb2m (Tm 5 52°C). This
effect was also noted for the complex of mb2m with Kd, com-
pared with the complex of hb2m with Kd (12), and more
dramatically, for the complex of mb2m with the nonclassical
murine class I protein T10 (9). We were able to analyze the
effect of bound peptide on UL18 stability by taking advantage
of the fact that soluble UL18 is only partially occupied with
endogenous peptides when it is expressed at high levels. Ad-
dition of a synthetic peptide corresponding to the sequence of
an endogenous peptide eluted from UL18 shifts the Tm to
66°C, thus formally demonstrating that UL18 binds this peptide
and suggesting a general method for assaying peptide binding
by UL18.
The different properties of UL18 and m144 revealed by this
study do not, in and of themselves, undermine the contention
that these molecules both function as surrogate class I pro-
teins, capable of engaging NK cell inhibitory receptors and
protecting cells that lack class I surface expression. Murine NK
cell inhibitory receptors are homodimeric C-type lectin super-
family proteins, whereas the majority of characterized human
inhibitory receptors are members of the immunoglobulin su-
perfamily (reviewed in references 22 and 35). It is therefore
conceivable that mouse NK inhibitory receptors would recog-
nize features of mouse class I MHC molecules different from
those recognized on human class I molecules by human inhib-
itory receptors. While there is no evidence yet of a direct
interaction between a mouse inhibitory receptor and m144,
recent results demonstrate that the presence of m144 inter-
feres with NK cell-mediated clearance of virus-infected cells in
vivo (14). The connection between UL18 and human NK cells
is less straightforward. A recent study reported that UL18
expressed on a human class I-negative B-lymphoblastoid cell
line inhibited NK cell lysis through interaction with the C-
lectin-like inhibitory receptor CD94 (40). However, we and
investigators at other laboratories have been unable to detect
cell surface expression of UL18 when its gene was transfected
into the same B-cell line (31b). Additional results indicate that
the presence of UL18 on virus-infected fibroblasts slightly aug-
ments, rather than inhibits, NK cell-mediated lysis (31b). A
probable host ligand for UL18 was recently identified as LIR-1,
a new immunoglobulin superfamily member related to human
NK inhibitory receptors (8). LIR-1 is expressed mainly on B
cells and monocytes, but only on a subset of NK cells; thus, it
is possible that the HCMV MHC homolog exerts its primary
effects on host cells other than NK cells. Further studies will be
necessary to resolve the roles of both m144 and UL18 in the
interactions of their respective viruses with the immune sys-
tems of the infected hosts. However, currently available data
suggest that the two homologs function differently, a hypoth-
esis that is consistent with the biochemical and structural dif-
ferences between m144 and UL18 observed in the present
study.
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